SAN ANTONIO – Dr. Jeanne Loring, Professor Emeritus of The Scripps Research Institute, Founding Director of the Center for Regenerative Medicine at Scripps, and founder of Aspen Neuroscience, has joined the Scientific Advisory Board of StemBioSys, Inc., (SBS) a privately-held, San Antonio-based biomedical company focused on a broad range of cell-based products.

StemBioSys CEO Bob Hutchens made the announcement, noting “Dr. Loring brings extraordinary research credentials to our Scientific Advisory Board. Among the many accomplishments of her career, she has led hallmark research studies on differentiating human induced pluripotent stem cells (iPSCs) into neurons that have important applications in treating neurological disease.” Hutchens noted that “StemBioSys is about to announce a new product directed at researchers in the neuronal space, Dr. Loring’s deep experience and world class capabilities in this area will be invaluable to StemBioSys as we work to commercialize and further develop this product. All of us at StemBioSys are extremely pleased that Dr. Loring has agreed to join our Scientific Advisory Board”.

Dr. John Harper, Chairman of StemBioSys’ Scientific Advisory Board added “Dr. Loring is on the leading edge of research for neuronal diseases and her expertise will be critical as the company enters the neuronal area. Dr. Loring also brings a wealth of experience working with companies such as ours, as well as a prestigious academic career.”

Dr. Loring said ”I’m looking forward to the development of new applications for StemBioSys’ technology and am pleased to have the opportunity to contribute to their success.”

As a pioneer in human stem cell research and expert in genomics and translational research, Dr. Loring serves on scientific advisory, bioethics, and scientific journal editorial boards, and is a member of numerous international grant review boards. She has decades of professional experience in both biotechnology and academia, which makes her a knowledgeable advisor for both academic groups and biotechnology companies. She is also a stem cell advocate who is committed to educating both scientists and the public about human stem cells and serves on the Board of Directors of a patient advocacy organization.

StemBioSys’ Scientific Advisory Board is chaired by Dr. John Harper. Dr. Harper is the Senior Vice President of R&D and Chief Technology Officer for Mimedx, a leader in wound care and regenerative medicine based in Marietta, GA. Other members of the Scientific Advisory Board include StemBioSys’ cofounders Dr. Xiao-Dong Chen and Dr. Steven Davis. Dr. Chris Navarra of the University of Texas San Antonio, and StemBioSys Chief Technology Officer Dr. Travis Block are also members of the Board.

The Scientific Advisory Board is charged with advising StemBioSys’ Board of Directors and management on a variety of scientific areas including identifying areas for further research, designing company supported research studies and reviewing the progress of the company’s scientific collaborations.

About StemBioSys, Inc.

StemBioSys, Inc. is a privately-held biomedical company. Our technologies represent the next evolution in cell research and are branded to the research market under the CELLvo™ label. The centerpiece of these technologies is our CELLvo™ Matrix. This cell derived microenvironment allows a variety of cells to replicate (multiply in number) more rapidly and express markers indicative of potency beyond that seen with traditional tissue culture substrates. The company also has several cell products isolated and expanded on our matrix. StemBioSys has also developed a novel approach for preclinical cardiac safety testing. This novel approach is currently being used by several commercial partners and the US Food & Drug Administration. Details of this approach were described in Nature Scientific Reports in November 2020.

For more information, contact Bob Hutchens, bob.hutchens@stembiosys.com or 914-661- 2077.